Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vapendavir for Rhinovirus in HSCT Patients
NCT03024177Phase 2Withdrawn
- Sponsor
- Vaxart, Inc.
- Primary completion
- Apr 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Vapendavir in rhinovirus infection, sponsored by Vaxart, Inc.. Status: withdrawn.
02
Drugs
Vapendavir
03
Conditions
rhinovirus infection
Beyond the preview
Go deeper on NCT03024177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03024177.